Key evidence for the efficacy of brentuximab vedotin in CTCL comes from the multicenter phase III ALCANZA study, which enrolled adults with CD30-positive MF or C-ALCL who had received at least 1 previous therapy [96]. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.